Welcome to our dedicated page for Zomedica SEC filings (Ticker: ZOMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Zomedica Corp. (ZOMDF) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret the information. Zomedica is an animal health company focused on diagnostic, therapeutic, and monitoring devices for equine and companion animals, and its SEC filings offer detailed insight into how it reports financial performance, risks, and strategic priorities.
Investors can use this page to review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment discussions for diagnostics, therapeutic devices, and development services, as well as commentary on consumable and capital revenue, margins, liquidity, and operating expenses. Current reports on Form 8-K, such as the filing dated November 4, 2025 referencing a press release on quarterly results, disclose material events and financial updates between regular reporting periods.
The platform also surfaces proxy statements and other governance-related documents, where available, and Form 4 insider transaction reports that show purchases and sales by directors and officers. These documents can be important for understanding executive incentives and ownership changes.
AI-powered tools on this page summarize lengthy filings, highlight key sections, and explain complex accounting or risk disclosures in plain language. Real-time connections to the SEC’s EDGAR system help ensure new filings appear promptly, so users can quickly locate the latest 10-K, 10-Q, 8-K, and Form 4 documents for Zomedica. This structure allows both individual and professional investors to navigate Zomedica’s regulatory history and evaluate its reported progress in animal health diagnostics and therapeutics.
Zomedica Corp. (ZOMDF) reported a director transaction involving stock appreciation rights. On 11/17/2025, the director acquired 2,126,959 stock appreciation rights with a conversion or exercise price of $0.1 per right. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Each right is linked to one share of common stock, so the transaction covers 2,126,959 underlying common shares. Following this grant, the director beneficially owns 2,126,959 derivative securities, held directly.
Zomedica Corp. (ZOMDF) reported an insider purchase on a Form 4. Senior Vice President, Sales, Kevin Klass bought 150,000 shares of common stock on November 13, 2025 at $0.097 per share. Following the transaction, he beneficially owned 5,784,101 shares, held directly.
Zomedica Corp. (ZOMDF) reported an insider purchase on Form 4. Kevin Klass, Sr Vice President, Sales, bought 120,000 shares of common stock on 11/10/2025 at $0.098 per share (transaction code P). Following this trade, he directly holds 5,634,101 shares.
Zomedica Corp. (ZOMDF) disclosed an insider purchase on a Form 4. Kevin Klass, the company’s Sr Vice President, Sales, bought 5,000 shares of common stock on 11/07/2025 at $0.095 per share (Transaction Code P). After this trade, he directly owns 5,514,101 shares.
Zomedica Corp. (ZOMDF) reported a Form 4 showing a purchase by Senior Vice President, Sales, Kevin Klass. On 11/06/2025, he acquired 253,007 shares of common stock at $0.08 per share (transaction code P), held as Direct ownership.
Following this transaction, Mr. Klass beneficially owned 5,509,101 shares of Zomedica common stock.
Zomedica Corp. furnished a Form 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company notes this information is being furnished and is not deemed “filed” under Section 18 of the Exchange Act. The filing lists Zomedica’s common shares trading as ZOMDF on the OTCQB and is dated November 4, 2025.
Zomedica Corp. reported Q3 results showing modest growth and continued losses. Net revenue rose to $8,095 (from $6,997) with gross profit of $5,436 (from $5,060). The company recorded a Q3 net loss of $6,121 (vs. $6,697). Year‑to‑date, revenue reached $21,559 (from $19,390) while net loss widened to $77,328, largely due to $55,833 of non‑cash impairment recorded earlier in 2025.
Cash and cash equivalents were $7,496 with $45,628 of current available‑for‑sale securities and $1,242 noncurrent. Total assets were $130,905 and shareholders’ equity was $119,688. Goodwill was fully written off in 2025, including $45,556 of impairments in Therapeutic Devices, and $8,300 of intangible impairments primarily in Diagnostics. Zomedica introduced a new Development Services segment in Q3 contributing $662 of revenue. Therapeutic Devices remained the core driver with Q3 revenue of $6,671, while Diagnostics delivered $762. Common shares outstanding were 979,949,668 as of November 3, 2025.